Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: DewDiligence_on_SI	10/19/2005 4:35:30 PM
	of 590

AMGN’s quarterly PR does not mention the pivotal trial in Panitumumab: biz.yahoo.com >> Panitumumab: Interim results from two ongoing trials support the ability of panitumumab to provoke tumor shrinkage when administered as a single agent every other week in patients with colorectal cancer who had failed prior intensive chemotherapy. These data will form part of a Biologics Licensing Application which Amgen, together with its partner Abgenix, intends to file beginning in the fourth quarter of 2005. The FDA has granted fast track status to panitumumab for this indication. << This is everything said about Pani in AMGN’s entire PR. Two things stand out here, both negative for AMGN / ABGX (IMHO): 1. They mention response rate but not PFS, which is the primary endpoint in the phase-3 trial that is completed 2. They mention the two “supporting” trials but not the main one—not even in passing. -- A reasonable, if somewhat aggressive, inference is that AMGN is preparing investors for the news that the PFS data will less than superb.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next